BPMC News and Press, Blueprint Medicines Corporation From 04/10/21

Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021 -- Preclinical data presented at AACR highlight four precision therapies with first- or best-in-class potential -- -- IND application cleared by F...

Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021 -- Presentations showcase the company's scientific leadership in precision oncology and hematology -- PR Newswire CAMBRIDGE,...

Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...

CStone Pharmaceuticals (CSPHF) announced that the National Medical Products Administration (“NMPA”) of China has approved Gavreto (pralsetinib) for the treatment of a certain group of adult patients with non-small cell lung cancer (“NSCLC”).The once-daily...

Stephen Mandel’s 13F portfolio value increased ~19% from $23.20B to $27.51B. The number of positions increased from 32 to 41. Lone Pine Capital increased MercadoLibre and DexCom while dropping PayPal and Capital One Financial. The top three positions are Shopify, Coupa Soft...

With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals,...

Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021 -- Range of presentations highlight the company's research productivity and broad precision therapy portfolio -- PR Newswire CAMBRIDGE, Mass. , ...

Blueprint Medicines ([[BPMC]] -1.6%) has announced that the European Medicines Agency has validated its Type II variation marketing authorization application for Ayvakyt (avapritinib) for advanced systemic mastocytosis.With the decision, the company says that the submission process is suffici...

Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis PR Newswire CAMBRIDGE, Mass. , March 3, 2021 /PRNewswire/ -- Blueprint Medici...

DCPH has seen some early success with ripretinib in 4th line and later GIST. However, the key to the mint is to show positive data in INTRIGUE, in 2nd line GIST for imatinib-refractory patients, and compared to sunitinib. That data will be out sometime in late 2021. For furt...